The submission of the MAGiC Catheter for regulatory approval in both Europe and the US is a critical step for Stereotaxis. It indicates the company's progress in developing new technologies and its commitment to expanding its product portfolio. This move is likely to be viewed positively by investors, as it represents potential future revenue growth and market expansion. However, the actual impact on the stock price will depend on the approval process's outcome and the market's perception of the product's potential.